Novo Nordisk Brings Wegovy to Indian Market Amid Rising Obesity Concerns

Published: 26 Jun 2025

Author: Precedence Research

Share :

India's booming weight-loss drug market witnessed an uphill battle with Denmark-based Novo Nordisk unleashing its super successful obesity treatment drug Wegovy within the country. It was launched just one month after its rival Eli Lilly launched the similarly hyped weight management drug Mounjaro. This puts increased pressure on a market with one of the largest and fastest-growing groups of obesity-afflicted individuals on the planet. Due to the current situation in India, which has been characterized by generalized obesity in 254 million adults and abdominal obesity in an even more worrying 351 million adults, it is anticipated that the demand for effective medical interventions grow in the forthcoming years.

Novo Nordisk has made the right decision to enter into the Indian market as it is one of the most successful pharmaceutical companies in the treatment of obesity worldwide. Wegovy, a compound of active agent semaglutide, proves to be strong in the international market in promoting weight loss and cardiovascular health. The cost is 17,345 rupees per Wegovy injection pen, which on a weekly basis puts the price at 4366 rupees. Distribution has already started, and the drug is likely to be available in pharmacies around the country at the end of the month.

India is in a state of obesity pandemic where this medical condition is likely to topple over the healthcare system. The combination of an inactive lifestyle, a long intake of processed food, and genetic factors proved to be the force that drives obesity to disturbing rates. In this regard, the introduction of prescription medications, such as Wegovy and Mounjaro, might be a shift in paradigm when it comes to treating obesity, not as a lifestyle-related problem.

Novo Nordisk would also be counting on its well-established diabetes care platform in India to promote the introduction of Wegovy. Having a firm base in endocrinology and a ravaging history among other doctors, the company is in a position to use the current networks to assemble quick force. Healthcare providers will have to be trained on the right dose, monitoring and follow-ups of the patients. Furthermore, the management of obesity through the use of injectable therapies would involve optimal attention and an overall plan of action.